CLINICAL EVALUATION OF CEFOTIAM IN INTERNAL MEDICINE, WITH SPECIAL REFERENCE TO INFECTIOUS DISEASE ASSOCIATED WITH HEMATOLOGICAL DISORDERS

Clinical evaluation of cefotiam (panspolin®), a new cephem antibiotics, was performed in the infectious disease associated with hematological disorders and in the respiratory system.In hematological dis orders, 40% of good and 25% of fair results were obtained in clinical effects.In respiratory infe...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of antibiotics 1981/08/25, Vol.34(8), pp.1148-1157
Main Authors: UCHIDA, TATSUMI, MATSUDA, SHIN, TANAKA, TETSUGORO, MUROI, SHUICHI, KIMURA, HIDEO, SATOH, TADASHI, YUI, TOKUO, SATOH, SHIN, FUJINO, AKIHISA, MITA, MASAYUKI, YAMADA, ZENMI, KARIYONE, SHIGEO, YOSHIDA, HIROSHI, KIKUTA, TSUTOMU, MIURA, NOBUO, ITOH, KURAO, IKEDA, KIYOHIRO, NEMOTO, TOSHIO, HIRAGURI, MAKOTO, SANBE, MITSUYOSHI, TAKEZAWA, MASATOSHI, NAKAMURA, YOSHIAKI, SATOH, YOSHIO, FUNAYAMA, SUSUMU, IGARASHI, TADAYUKI, OGIU, ATSUHIRO, MASEKI, NOBUO, KOMATSU, MASAFUMI
Format: Article
Language:Japanese
Subjects:
Adolescent
Adult
Aged
Bacterial Infections - drug therapy
Cefotaxime - analogs & derivatives
Cefotaxime - therapeutic use
Cefotiam
Drug Evaluation
Female
Hematologic Diseases - complications
Humans
Male
Middle Aged
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Clinical evaluation of cefotiam (panspolin®), a new cephem antibiotics, was performed in the infectious disease associated with hematological disorders and in the respiratory system.In hematological dis orders, 40% of good and 25% of fair results were obtained in clinical effects.In respiratory infections, however, 92% of good results were obtained.Opportunistic infection due to Gram-negative bacilli are often experienced in patinets with leukemia.Since cefotiam has sufficient bacteriocidal effects in broad spectrum, it would be a good therapeutic agent against infectious diseases associated with hematological disorders.
ISSN:0368-2781
2186-5477
DOI:10.11553/antibiotics1968b.34.1148